BRVE · Braveheart Bio, Inc.

Each share of Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-4.38 basis upon the closing of the Issuer's initial public offering on August 7, 2026 without payment of consideration. The Series A Preferred Stock has no expiration date.

These securities are held of record by OrbiMed Private Investments IX, LP ("OPI IX"). OrbiMed Capital GP IX LLC ("GP IX") is the general partner of OPI IX. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI IX. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI IX.

This report on Form 4 is jointly filed by OrbiMed Advisors, GP IX, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Erez Chimovits, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock automatically converted into Common Stock on a one-for-4.38 basis without payment of consideration. The Series A Preferred Stock had no expiration date.

Forbion Growth III Management B.V. ("Forbion Growth III Management") is the director of Forbion Growth Opportunities Fund III Cooperatief U.A. (the "Forbion Growth III") and may be deemed to have voting and dispositive power over the securities beneficially owned by the Forbion Growth III. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose.

Each share of Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-4.38 basis upon the closing of the Issuer's initial public offering on August 7, 2026 without payment of consideration. The Series A Preferred Stock has no expiration date.

These securities are held of record by OrbiMed Private Investments IX, LP ("OPI IX"). OrbiMed Capital GP IX LLC ("GP IX") is the general partner of OPI IX. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI IX. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI IX.

This report on Form 4 is jointly filed by OrbiMed Advisors, GP IX, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Erez Chimovits, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock automatically converted into Common Stock on a one-for-4.38 basis without payment of consideration. The Series A Preferred Stock had no expiration date.

Forbion Ventures VII Management B.V. ("Forbion VII Director") is the director of Forbion Ventures Fund VII Cooperatief U.A. (the "Forbion Ventures VII") and may be deemed to have voting and dispositive power over the securities beneficially owned by the Forbion Ventures VII. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose.

Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.

These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by Genesis and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by Genesis.

This report on Form 4 is jointly filed by OrbiMed Advisors, GP IX, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Erez Chimovits, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

Series A Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 4.38-for-1 basis. The Series A Preferred Stock had no expiration date.

The reported securities are held by AH Bio Fund IV, L.P. ("AH Bio Fund IV"), for itself and as nominee for AH Bio Fund IV-B, L.P., AH 2022 Annual Fund, L.P., AH 2022 Annual Fund-B, L.P., AH 2022 Annual Fund-QC, L.P. and CLF Partners III, LP. AH Equity Partners Bio IV, L.L.C. ("AH EP Bio IV") is the general partner of AH Bio Fund IV and has sole voting and dispositive power with regard to the securities held by AH Bio Fund IV for itself and as nominee. The managing members of AH EP Bio IV are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund IV for itself and as nominee.

(Continued from Footnote 2) Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of the securities held by AH Bio Fund IV for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.

Each share of Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-4.38 basis upon the closing of the Issuer's initial public offering on August 7, 2026 without payment of consideration. The Series A Preferred Stock has no expiration date.

These securities are held of record by OrbiMed Private Investments IX, LP ("OPI IX"). OrbiMed Capital GP IX LLC ("GP IX") is the general partner of OPI IX. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI IX. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI IX.

Each of the Reporting Person, OrbiMed Advisors, GP IX, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP IX, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

The non-voting Series A preferred stock (the "Preferred Stock") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock automatically converted into Common Stock on a one-for-4.38 basis without payment of consideration. The Series A Preferred Stock had no expiration date.

Forbion Ventures VII Management B.V. ("Forbion VII Director") is the director of Forbion Ventures Fund VII Cooperatief U.A. (the "Forbion Ventures VII") and may be deemed to have voting and dispositive power over the securities beneficially owned by the Forbion Ventures VII. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose.

Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.

These securities are held of record by OrbiMed Private Investments IX, LP ("OPI IX"). OrbiMed Capital GP IX LLC ("GP IX") is the general partner of OPI IX. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI IX. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI IX.

This report on Form 4 is jointly filed by OrbiMed Advisors, GP IX, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Erez Chimovits, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

Forbion Ventures VII Management B.V. ("Forbion VII Director") is the director of Forbion Ventures Fund VII Cooperatief U.A. (the "Forbion Ventures VII") and may be deemed to have voting and dispositive power over the securities beneficially owned by the Forbion Ventures VII. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose.

Series A Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 4.38-for-1 basis. The Series A Preferred Stock had no expiration date.

The reported securities are held by AH Bio Fund IV, L.P. ("AH Bio Fund IV"), for itself and as nominee for AH Bio Fund IV-B, L.P., AH 2022 Annual Fund, L.P., AH 2022 Annual Fund-B, L.P., AH 2022 Annual Fund-QC, L.P. and CLF Partners III, LP. AH Equity Partners Bio IV, L.L.C. ("AH EP Bio IV") is the general partner of AH Bio Fund IV and has sole voting and dispositive power with regard to the securities held by AH Bio Fund IV for itself and as nominee. The managing members of AH EP Bio IV are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund IV for itself and as nominee.

(Continued from Footnote 2) Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of the securities held by AH Bio Fund IV for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.

The non-voting Series A preferred stock (the "Preferred Stock") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

Forbion Growth III Management B.V. ("Forbion Growth III Management") is the director of Forbion Growth Opportunities Fund III Cooperatief U.A. (the "Forbion Growth III") and may be deemed to have voting and dispositive power over the securities beneficially owned by the Forbion Growth III. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose.

Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock automatically converted into Common Stock on a one-for-4.38 basis without payment of consideration. The Series A Preferred Stock had no expiration date.

Forbion Growth III Management B.V. ("Forbion Growth III Management") is the director of Forbion Growth Opportunities Fund III Cooperatief U.A. (the "Forbion Growth III") and may be deemed to have voting and dispositive power over the securities beneficially owned by the Forbion Growth III. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose.

Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.

These securities are held of record by OrbiMed Private Investments IX, LP ("OPI IX"). OrbiMed Capital GP IX LLC ("GP IX") is the general partner of OPI IX. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI IX. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI IX.

Each of the Reporting Person, OrbiMed Advisors, GP IX, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP IX, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.

These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by Genesis and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by Genesis.

Each of the Reporting Person, OrbiMed Advisors, GP IX, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP IX, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

Each share of Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-4.38 basis upon the closing of the Issuer's initial public offering on August 7, 2026 without payment of consideration. The Series A Preferred Stock has no expiration date.

These securities are held of record by OrbiMed Private Investments IX, LP ("OPI IX"). OrbiMed Capital GP IX LLC ("GP IX") is the general partner of OPI IX. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI IX. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI IX.

Each of the Reporting Person, OrbiMed Advisors, GP IX, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP IX, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

The reported securities are held by AH Bio Fund IV, L.P. ("AH Bio Fund IV"), for itself and as nominee for AH Bio Fund IV-B, L.P., AH 2022 Annual Fund, L.P., AH 2022 Annual Fund-B, L.P., AH 2022 Annual Fund-QC, L.P. and CLF Partners III, LP. AH Equity Partners Bio IV, L.L.C. ("AH EP Bio IV") is the general partner of AH Bio Fund IV and has sole voting and dispositive power with regard to the securities held by AH Bio Fund IV for itself and as nominee. The managing members of AH EP Bio IV are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund IV for itself and as nominee.

(Continued from Footnote 2) Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of the securities held by AH Bio Fund IV for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.

1/36th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of July 23, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

The shares underlying the stock option will vest in full upon the earlier of (i) August 5, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date.

The shares underlying the stock option will vest in full upon the earlier of (i) August 5, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date.

The shares underlying the stock option will vest in full upon the earlier of (i) August 5, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date.

Pursuant to an agreement with OrbiMed Advisors LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof to OrbiMed Advisors LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments IX, LP.

The shares underlying the stock option will vest in full upon the earlier of (i) August 5, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date.

1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of July 23, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

The shares underlying the stock option will vest in full upon the earlier of (i) August 5, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date.

1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of July 23, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of July 23, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.